Vaccine adjuvant now being trialed as an Alzheimer's vaccine at Brigham and Women's
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2021)
Protollin is a drug initially formulated as a vaccine adjuvant.[1][2] It is composed of lipopolysaccharides derived from the Shigella flexneri or Pleisiomonas shigelloides bacterium combined with hydrophobic outer membrane proteins derived from Neisseria meningitidis.[3][4]
On November 16, 2021, Brigham and Women's Hospital announced that it was beginning a Phase I clinical trial of Protollin as a nasally-delivered vaccine to activate the body's immune response against amyloid proteins that form in the brain and are thought to contribute to the symptoms of Alzheimer's disease.[5][6]
^"Human trials for nasal Alzheimer's vaccine due to start". Newsweek. 2021-11-17. Retrieved 2021-11-19.
^"First human trial of Alzheimer's disease nasal vaccine to begin at Boston hospital". www.cbsnews.com. CBS News. 16 November 2021. Retrieved 2021-11-19.
Protollin is a drug initially formulated as a vaccine adjuvant. It is composed of lipopolysaccharides derived from the Shigella flexneri or Pleisiomonas...